Avacta Strengthens Governance with Biotech Finance Veteran as Audit Chair
Event summary
- Avacta appoints Mats Blom as Board Director and Audit Committee Chair effective September 14, 2026.
- Paul Fry to step down from the Board on September 30, 2026, after 7 years of service.
- Blom brings extensive CFO experience in biotech, including roles at Zealand Pharma and Active Biotech.
- Blom currently chairs Egetis Therapeutics and serves on Hansa Biopharma’s board.
- Avacta’s pre|CISION® platform remains core focus as company advances clinical-stage oncology programs.
The big picture
Avacta’s appointment of Mats Blom reflects a strategic emphasis on financial governance as the company navigates clinical-stage development of its tumor-activated oncology platform. Blom’s background in biotech finance and public listings aligns with Avacta’s push toward clinical milestones and potential partnerships. The move underscores the importance of audit oversight in a capital-intensive sector where regulatory and commercial risks are high.
What we're watching
- Governance Dynamics
- How Mats Blom’s financial expertise will shape Avacta’s strategic oversight during clinical-stage development.
- Clinical Milestones
- Whether the leadership transition impacts the pace of pre|CISION® platform advancements.
- Partner Engagement
- The extent to which Blom’s biotech network influences potential collaborations or funding opportunities.
Related topics